drugset
drugset / Trial / NCT00387426

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

NCT00387426 ↗

Phase 2 Terminated 14 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well sunitinib works in treating patients with idiopathic myelofibrosis. Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the abnormal cells.

Timeline

Start
2006-09
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule — Oral

Indications

T-cell large granular lymphocyte leukemia acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, t(16;16)(p13.1;q22) acute promyelocytic leukemia acute undifferentiated leukemia adult acute lymphoblastic leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia hairy cell leukemia leukemia, myeloid, accelerated-phase mast cell leukemia primary myelofibrosis prolymphocytic leukemia therapy related acute myeloid leukemia and myelodysplastic syndrome